T A B L E O F C O N T E N T S
2: MD -1.32, 95% CI -2.00 to -0.64, P = 0.001; day 3: MD -1.51, 95% CI -1.88 to -1.14, P < 0.00001). The effects of improving clinical score were observed in both outpatients and inpatients. Four emergency department-based trials did not show any significant short-term effects (30 to 120 minutes) of up to three doses of nebulised 3% saline in improving clinical score and oxygen saturation. No significant adverse events related to hypertonic saline inhalation were reported.
Authors' conclusions
Current evidence suggests nebulised 3% saline may significantly reduce the length of hospital stay among infants hospitalised with non-severe acute viral bronchiolitis and improve the clinical severity score in both outpatient and inpatient populations.
P L A I N L A N G U A G E S U M M A R Y

Hypertonic saline solution administered via nebuliser for acute bronchiolitis in infants
Acute viral bronchiolitis is the most common lower respiratory tract infection in infants up to two years old. Currently there is no effective treatment so standard treatment remains supportive care. Airway oedema (abnormal accumulation of fluid) and mucus plugging can cause wheezing and difficulty breathing in these patients. Nebulised hypertonic saline may be a beneficial treatment to manage acute bronchiolitis because it can improve airway hygiene. This review was conducted to assess the effects of hypertonic (≥ 3%) saline solution administered via a nebuliser in infants with acute bronchiolitis, compared with nebulised normal (0.9%) saline. The establishment of a therapeutic role for hypertonic saline solution may provide a cheap and effective therapy for these patients.
We included 11 randomised trials involving 1090 infants with mild to moderate bronchiolitis. All but one of the 11 trials are considered as high-quality studies with low risk of error (i.e. bias) in their conclusions. Meta-analysis suggests that nebulised hypertonic saline could lead to a reduction of 1.2 days in the mean length of hospital stay among infants hospitalised for non-severe acute bronchiolitis and improve the clinical severity score in both outpatient and inpatient populations. No significant short-term effects (at 30 to 120 minutes) of one to three doses of nebulised hypertonic saline were observed among emergency department patients. However, more trials are needed to address this question. There were no significant adverse effects noted with the use of nebulised hypertonic saline when administered along with bronchodilators.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nebulised hypertonic saline compared with nebulised 0.9% saline for acute bronchiolitis in infants Patient or population: infants up to 24 months of age with acute bronchiolitis Settings: outpatient, emergency department or inpatient Intervention: nebulised hypertonic saline (≥ 3%) Comparison: nebulised 0.9% saline
Outcomes
Illustrative comparative risks* (95% CI) Relative effect (95% CI)
Number of participants (studies)
Quality of the evidence (GRADE)
Comments
Assumed risk Corresponding risk
Nebulised 0.9% saline Nebulised hypertonic saline
Length of hospital stay (days)
The mean length of hospital stay ranged across control groups from 3.5 to 7. 4 
days
The mean length of hospital stay in the intervention groups was on average 1.15 days shorter (95% CI -1.49 to -0.82) 500 (6 inpatient trials)
⊕⊕⊕⊕ high
Clinical severity score (post-treatment) at day 1 The clinical score of Wang 1992 in which each of 4 symptoms and signs (respiratory rate, wheezing, retraction and general condition) was graded on a scale of 0 to 3, with increased severity receiving a higher score
The mean clinical severity score ranged across control groups from 3.97 to 8.8
The mean clinical severity score in the intervention groups was on average 0.88 lower (95% CI -1.36 to -0.39) 640 (7 trials: 1 outpatient, 1 emergency department, 5 inpatients)
Given the small number of participants, the small number of inhalations (up to three doses) and short monitoring time (up to 120 minutes post-inhalation), further large RCTs with multiple doses of hypertonic saline over a longer period of time are still needed for evaluating the effect of nebulised hypertonic saline in improving clinical score among infants with acute bronchiolitis seen in emergency departments Clinical severity score (post-treatment) at day 2 The clinical score of Wang 1992 as described above
The mean clinical severity score ranged across control groups from 3.8 to 8.2
The mean clinical severity score in the intervention groups was on average 1.32 lower (95% CI -2.00 to -0.64) 636 (7 trials: 1 outpatient, 1 emergency department, 5 inpatients)
The same comments as described above Clinical severity score (post-treatment) at day 3 The clinical score of Wang 1992 as described above
The mean clinical severity score ranged across control groups from 2.9 to 7.6
The mean clinical severity score in the intervention groups was on average 1.51 lower (95% CI -1.88 to -1.14) 439 (6 trials: 1 outpatient, 5 inpatients)
The same comments as described above 
Rate of hospitalisation
B A C K G R O U N D Description of the condition
Acute bronchiolitis is the most frequent lower respiratory tract infection in infants (Klassen 1997a). Most cases are viral in origin, with the leading cause being the respiratory syncytial virus (RSV).
Other less common pathogens include parainfluenza viruses, adenovirus, influenza A and B, rhinovirus, human metapneumovirus and Mycoplasma pneumoniae (M. pneumoniae) (Garcia-Garcia 2006; Henderson 1979; Jacques 2006; Rose 1987; Shay 2001) . Virtually all infants are infected by RSV by the age of two years, around 40% to 50% develop involvement of the lower respiratory tract and 1% to 2% develop severe disease leading to hospitalisation (Meissner 2003; Rakshi 1994; Shay 1999) . Over the last few decades, an increasing trend in the rate of hospitalisation of children with bronchiolitis has been observed in the USA and Canada (Langley 2003; Njoo 2001; Shay 1999) . In acute bronchiolitis, the principal pathological findings include a peribronchial infiltrate of inflammatory cells, mucosal and submucosal oedema, necrosis and desquamation of ciliated epithelial cells, proliferation of cuboidal cells and excess mucus secretion (Panitch 1993; Wohl 1978) . The combination of airway wall swelling, sloughing of necrotic debris, increased mucus production and impaired secretion clearance eventually leads to airway obstruction, gas trapping, atelectasis and impaired gas exchange. The diagnosis of acute bronchiolitis is usually based on clinical grounds. Despite the definition of bronchiolitis differing from country to country, it is generally accepted that acute bronchiolitis refers to the first episode of acute wheezing in children less than two years of age, starting as a viral upper respiratory infection (coryza, cough or fever) (Panitch 1993). These criteria for diagnosis of acute bronchiolitis have also been widely used in clinical trials (Bertrand 2001; Klassen 1997b; Schuh 1992; Wainwright 2003; Zhang 2003) . Direct fluorescent antibody tests, enzyme immunoassay techniques and cultures of the nasopharyngeal aspirate may be used to identify the causative pathogen.
Description of the intervention
The standard treatment for acute bronchiolitis remains supportive care and includes ensuring adequate oxygen exchange, fluid intake and feeding of the infant (Panitch 2003; Wohl 2003) . There is a lack of convincing evidence for any other therapy. As airway oedema and mucus plugging are the predominant pathological features in acute bronchiolitis, any therapeutic modality which can reduce these pathological changes and improve the clearance of airway secretions may be beneficial. Epinephrine has a theoretical effect on acute bronchiolitis because it contains alpha adrenergic properties which lead to vasoconstriction and reduction of airway oedema (Wohl 1978 
How the intervention might work
Hypertonic saline solution has been shown to increase mucociliary clearance in normal individuals and in patients with asthma, bronchiectasis, cystic fibrosis and sinonasal diseases (Daviskas 1996; Kellett 2005; Shoseyov 1998; Wark 2009 ). Such benefits would also be expected in infants with acute bronchiolitis (Mandelberg 2010). The postulated mechanisms of benefit are as follows: 1) hypertonic saline induces an osmotic flow of water into the mucus layer, rehydrating the airway surface liquid and improving mucus clearance (Mandelberg 2010; Robinson 1997) ; 2) hypertonic saline breaks the ionic bonds within the mucus gel, thereby reducing the degree of cross-linking and entanglements and lowering the viscosity and elasticity of the mucus secretion (Ziment 1978); 3) hypertonic saline stimulates cilial beat via the release of prostaglandin E2 (Assouline 1977). Moreover, by absorbing water from the mucosa and submucosa, hypertonic saline solution can theoretically reduce oedema of the airway wall in infants with acute bronchiolitis (Mandelberg 2003; Mandelberg 2010; Sarrell 2002) . Hypertonic saline inhalation can also cause sputum induction and cough, which can help to clear the sputum outside of the bronchi and thus improve airway obstruction (Mandelberg 2003) . The above mentioned theoretical benefits provide the rationale for the treatment of acute bronchiolitis with nebulised hypertonic saline solution.
Why it is important to do this review
The hypothesis of this review is that nebulised hypertonic saline solution is beneficial in the management of acute bronchiolitis as assessed by clinically relevant outcomes, both in inpatients and outpatients. The establishment of a therapeutic role for hypertonic saline solution in acute bronchiolitis has relevant clinical implications. This modality may provide a cheap and effective therapy for children with acute bronchiolitis.
O B J E C T I V E S
To assess the effects of nebulised hypertonic (≥ 3%) saline solution in infants with acute viral bronchiolitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and quasiRCTs (where there is alternate allocation to treatment and control groups) in this review. We excluded studies which included patients who had had recurrent wheezing or were intubated and ventilated, and studies which assessed pulmonary function alone.
Types of participants
Infants up to 24 months of age with the diagnosis of acute bronchiolitis. Acute bronchiolitis was defined as the first episode of acute wheezing associated with clinical evidence of a viral infection (cough, coryza or fever). Confirmation of viral aetiology was not necessary for study inclusion. We included studies of inpatients, emergency department patients or outpatients.
Types of interventions
1. Nebulised hypertonic saline alone versus nebulised 0.9% saline 2. Nebulised hypertonic saline plus bronchodilator versus nebulised 0.9% saline 3. Nebulised hypertonic saline plus bronchodilator versus nebulised 0.9% saline plus same bronchodilator 4. Nebulised hypertonic saline alone or plus bronchodilator versus no intervention Given the very limited number of studies that were identified initially, we added the comparison of nebulised hypertonic saline alone versus nebulised 0.9% saline. Hypertonic saline was defined as a concentration of saline greater than or equal to 3%. Science (1955 to May 2013 . See Appendix 1 for details of the previous search. We used the following search strategy to search MEDLINE and CENTRAL. As there were so few search results we used no filter to identify randomised trials in MEDLINE. We adapted the search terms to search EMBASE (Appendix 2), LILACS (Appendix 3), CINAHL (Appendix 4) and Web of Science (Appendix 5). 
Types of outcome measures
MEDLINE (OVID)
1
Data collection and analysis
Selection of studies
Two review authors (LZ, RAM) independently assessed the titles and abstracts of all studies identified by the searches. We obtained the full articles when they appeared to meet the inclusion criteria or there were insufficient data in the title and abstract to make a clear decision for their inclusion. We excluded articles that did not meet the inclusion criteria. We noted the reasons for their exclusion (see Characteristics of excluded studies table). We resolved any disagreements between the two review authors about study inclusion by discussion.
Data extraction and management
One review author (LZ) extracted study details from the included trials using a standardised data extraction form. These were checked by another review author (RAM). We resolved any disagreements by discussion. We entered the extracted data into RevMan 2012. We extracted the following data.
1. Study characteristics: publication status, year, country of study and setting.
2. Methods: method of allocation, blinding of participants and assessment of outcome, exclusion of participants after randomisation, proportion of follow-up losses and intention-totreat analysis.
3. Participants: sample size, age, sex, and inclusion and exclusion criteria.
4. Intervention: concentration of saline, volume of saline, interval of administration, treatment duration and cointerventions.
5. Control: nebulised 0.9% saline or nil. 6. Outcomes: primary and secondary outcomes as described previously. For continuous outcomes, we extracted sample size, mean and standard deviation for each group. For dichotomous outcomes, we extracted sample size and number of events for each group. When the trial recruited multiple groups, we combined them into the hypertonic saline group and the normal saline group. In the trial of Al-Ansari 2010, we combined 5% saline group and 3% saline group into the hypertonic saline group. In the trial of Anil 2010, we combined four groups (3% saline mixed with epinephrine, 3% saline mixed with salbutamol, 0.9% saline mixed with epinephrine and 0.9% saline mixed with salbutamol) into the hypertonic saline group and the normal saline group. In the trial of Ipek 2011, we combined four groups (3% saline plus salbutamol, 3% saline alone, 0.9% saline plus salbutamol and 0.9% saline alone) into the hypertonic saline group and the normal saline group.
Assessment of risk of bias in included studies
Two review authors (LZ, RAM) independently assessed the potential risk of bias in included studies according to The Cochrane Collaboration's 'Risk of bias' tool (Higgins 2011). Assessment results are summarised in the 'Risk of bias' tables.
Measures of treatment effect
We synthesised dichotomous data using risk ratios (RR) and 95% confidence intervals (CI) as the effect measures. We used the mean difference (MD) and 95% CI as the metrics of effect size for continuous outcomes.
Dealing with missing data
We contacted three principal investigators (Kuzik 2007; Luo 2010; Mandelberg 2003) for additional data on clinical score and methodological aspects. All three trial authors responded and provided the requested data.
Assessment of heterogeneity
We assessed heterogeneity in results between studies using the Cochrane Q test (P < 0.1 considered significant) and the I 2 statistic. The I 2 statistic ranges from 0% to 100% and measures the degree of inconsistency across studies, with values of 25%, 50% and 75% corresponding to low, moderate and high heterogeneity, respectively (Higgins 2003) .
Assessment of reporting biases
Reporting biases, especially publication bias, may be expected to occur in the majority of systematic reviews. Unfortunately there is no reliable method to detect publication bias. To minimise the potential reporting biases, we used no language restrictions for the literature searches. We contacted experts and searched the currently available trial registration databases for additional published or unpublished trials.
Data synthesis
We performed the meta-analyses using the Cochrane statistical package RevMan 5.2 (RevMan 2012). We used the random-effects model for meta-analyses. We conducted random effects metaregression using Stata version 11.0 (Stata-Corp, College Station, TX, USA). Whenever possible, we used intention-to-treat (ITT) analysis data.
Subgroup analysis and investigation of heterogeneity
We performed pre-planned subgroup analysis according to patient status (outpatient, emergency department patient and inpatient). The severity of disease and treatment regime (concentration of saline, volume, interval of inhalation, drug delivery and duration of treatment) may also contribute to heterogeneity in effect sizes across studies. We conducted post hoc random-effects meta-regression using Restricted Maximum Likelihood Estimation (REML) to explore these possible causes of heterogeneity between studies.
R E S U L T S Description of studies
Results of the search
The initial search of electronic databases in 2007 retrieved a total of 261 citations (Zhang 2008). After reviewing the titles and abstracts, we identified seven papers as being potentially relevant, which we reviewed in full text. Four trials met all the criteria for study selection and were included in the initial review. The update search in 2010 (Zhang 2011) retrieved 39 citations and three additional trials were identified and included in the updated review. This 2013 updated search retrieved 158 citations from the electronic databases. From them we identified four new trials. Therefore, a total of 11 trials were included in this updated review. See the Characteristics of included studies table.
Included studies
All 11 studies were randomised, double-blind, parallel-group, controlled trials. One study was a multi-centre trial involving one hospital in the United Arab Emirates and two hospitals in Canada 
Interventions
The concentration of hypertonic saline was defined at 3% in all but one trial (Al-Ansari 2010), in which two concentrations (3% and 5%) were used. Treatment regimens of nebulised hypertonic saline (volume, interval of administration, addition of bronchodilator and treatment duration) varied across studies, especially emergency department-based trials (Table 1) . Oxygen or compressed air-driven jet nebulisers were used for drug deliveries in all but one trial (Tal 2006) , in which ultrasonic nebulisers were utilised. 
Excluded studies
We excluded four studies from the review. The reasons for exclusion are summarised in the Characteristics of excluded studies table.
Risk of bias in included studies
All but one (Ipek 2011) of the 11 included trials were of high methodological quality with low risk of bias. Summary assessment of six key domains is described below and presented in Figure 1 . In the trial of Giudice 2012, study solutions were prepared by the local hospital pharmacy, but the method of allocation concealment was not described. The trial of Ipek 2011 assigned patients to treatment groups according to the consecutive order of their admission to the emergency department.
Blinding
In all but one (Ipek 2011) of the 11 included trials, participants, care providers and investigators were blinded to group assignment. The trial of Ipek 2011 was stated to be double-blinded, but no details were provided.
Incomplete outcome data
The number of participants with missing data was small in all 11 trials. Thus, incomplete outcome data may not be a source of bias in this review. Intention-to-treat (ITT) analysis was used by three trials (Grewal 2009; Kuzik 2007; Sarrell 2002) .
Selective reporting
There was no evidence of selective reporting of outcomes in the included studies.
Other potential sources of bias
No other potential sources of bias were observed in the included trials.
Effects of interventions
See: Summary of findings for the main comparison Eleven RCTs involving 1090 infants with mild to moderate acute viral bronchiolitis (500 inpatients, 65 outpatients and 525 emergency department patients) compared nebulised hypertonic saline to nebulised 0.9% saline.
Primary outcome 1. Length of hospital stay or time taken to be ready for discharge (inpatients)
All six The pooled results show that infants treated with nebulised 3% saline had a statistically significant shorter mean length of hospital stay compared to those treated with nebulised 0.9% saline, with a pooled mean difference (MD) of -1.15 days (95% confidence interval (CI) -1.49 to -0.82, P < 0.00001) (Analysis 1.1) ( Figure  2 ). This represents a 22.7% reduction from the mean length of hospital stay in the 0.9% saline group. There was no significant heterogeneity in results between studies (P = 0.21; I 2 statistic = 30%). ) with a combined total of 380 participants assessed the efficacy of nebulised 3% saline in reducing the risk of hospitalisation. There was no significant reduction in rate of hospitalisation. The pooled risk ratio (RR) was 0.63 (95% CI 0.37 to 1.07, P = 0.09) (Analysis 1.2) (Figure 3 ). There was no significant heterogeneity between studies (P = 0.99; I 2 statistic = 0%). patients also demonstrated significant benefits of hypertonic saline in reducing clinical score (pooled MD -0.99, 95% CI -1.48 to -0.50, P < 0.00001) (Analysis 1.3.3), in spite of significant heterogeneity between studies (P = 0.02; I 2 statistic = 67%). In contrast, one emergency department trial (Al-Ansari 2010) with 171 patients did not show the superiority of hypertonic saline over normal saline in reducing clinical score (MD -0.09, 95% CI -0.51 to 0.33, P = 0.68). The pooled results from all seven trials showed a significantly lower post-inhalation clinical score favouring treatment with nebulised hypertonic saline over nebulised 0.9% saline on the first day of treatment, with a pooled MD of -0.88 (95% CI -1.36 to -0.39, P = 0.0004) (Analysis 1.3) (Figure 4 ). This difference represents a 13.6% reduction from the mean clinical score in the 0.9% saline group on the first day of treatment. There was significant heterogeneity in results between studies (P = 0.0001; I 2 statistic = 78%). On the second day of treatment, one outpatient trial (n = 65) (Sarrell 2002) showed a lower post-inhalation clinical score in the 3% saline group compared to the 0.9% saline group, with a MD of -2.0 (95% CI -2.93 to -1.07, P < 0.0001) (Analysis 1.4.1). A significant difference between the treatment and control groups was also observed among 400 inpatients (Giudice 2012; Luo 2010; Luo 2011; Mandelberg 2003; Tal 2006) , with a pooled MD of -1.45 favouring 3% saline group (95% CI -2.06 to -0.85, P < 0.00001) (Analysis 1.4.3). There was significant heterogeneity between inpatient trials (P = 0.0008; I 2 statistic = 79%). One emergency department trial (n = 171) (Al-Ansari 2010) failed to show significant benefits of hypertonic saline in reducing clinical score (MD -0.27, 95% CI -0.63 to 0.09, P = 0.14) (Analysis 1.4.2). The meta-analysis of seven trials demonstrated the superiority of nebulised 3% saline over 0.9% saline in reducing the post-inhalation clinical score on the second day of treatment, with a pooled MD of -1.32 (95% CI -2.00 to -0.64, P < 0.0001) (Analysis 1.4) ( Figure 5 ). This difference represents a 23.0% reduction from the mean clinical score in the 0.9% saline group for the second day of treatment. Significant heterogeneity was found between studies (P < 0.00001; I 2 statistic = 89%). On the third day of treatment, one outpatient trial (n = 65) (Sarrell 2002) showed a lower post-inhalation clinical score in the 3% saline group compared to the 0.9% saline group, with a MD of -2.64 (95% CI -3.85 to -1.43, P < 0.0001) (Analysis 1.5.1). The five inpatient trials (n = 374) (Giudice 2012; Luo 2010; Luo 2011; Mandelberg 2003; Tal 2006 ) also showed a lower post-inhalation clinical score in the 3% saline group (pooled MD -1.44, 95% CI -1.78 to -1.10, P < 0.00001) (Analysis 1.5.2). Moderate heterogeneity was observed between inpatient trials (P = 0.08; I 2 statistic = 53%). The pooled results from these five trials demonstrated the superiority of nebulised 3% saline over 0.9% saline in reducing the post-inhalation clinical score on the third day of treatment (pooled MD -1.51, 95% CI -1.88 to -1.14, P < 0.00001) (Analysis 1.5) (Figure 6 ). This difference represents a 29.4% reduction from the mean clinical score in the 0.9% saline group. There was significant heterogeneity between studies (P = 0.04; I 2 statistic = 58%). To explore the possible causes of heterogeneity across studies regarding the effect size of hypertonic saline on clinical score during the first three days of treatment, we performed post hoc metaregression in which the effect estimate (mean difference of clinical score) is predicated by one or more explanatory variables (potential effect modifiers or covariates). The small number of studies allowed us to include only one relevant covariate in the model which was the severity of bronchiolitis assessed by clinical score in the 0.9% saline group. The meta-regression yielded a regression coefficient of 0.05 (95% CI -0.15 to 0.25, P = 0.59), suggesting that the severity of disease did not significantly influence the effect size of hypertonic saline. Three emergency department-based trials (Anil 2010; Grewal 2009; Ipek 2011 ) assessed short-term effects (30 to 120 minutes) of up to three doses of nebulised 3% saline in improving clinical score among infants with acute bronchiolitis. No significant benefits were observed. There were also no significant effects on oxygen saturation. Another emergency department trial (Al-Ansari 2010) showed a small but statistically significant lower clinical score favouring treatment with nebulised 5% saline over nebulised 0.9% saline at 48 hours after randomisation (3.69 ± 1.09 versus 4.12 ± 1.11, P = 0.04) but not 24 hours after randomisation (3.75 ± 1.27 versus 3.97 ± 1.40, P = 0.38). This trial did not find a significant difference in clinical score at 24 hours and 48 hours after randomisation between 3% saline and 0.9% saline.
Rate of readmission to hospital
Three emergency department trials with a total of 366 participants (Al-Ansari 2010; Anil 2010; Grewal 2009) used rate of readmission as an outcome. The pooled results of these trials did not demonstrate significant benefits of nebulised hypertonic saline in reducing the risk of readmission (pooled RR 1.05, 95% CI 0.62 to 1.76, P = 0.87) (Analysis 1.6). There was no significant heterogeneity between studies (P = 0.81; I 2 statistic = 0%).
Haemoglobin saturation (oximetry)
Five trials (Al-Ansari 2010; Anil 2010; Grewal 2009; Ipek 2011; Mandelberg 2003) did not find a significant difference between the hypertonic saline group and the 0.9% saline group in terms of room air saturation of oxyhaemoglobin throughout the study period.
Respiratory rate
One trial (Ipek 2011) reported no difference in respiratory rate between the hypertonic saline group and the 0.9% saline group.
Heart rate
Four trials (Anil 2010; Ipek 2011; Mandelberg 2003; Sarrell 2002) reported no difference in pulse rate between the hypertonic saline group and the 0.9% saline group.
Time for the resolution of symptoms/signs
Two trials (Luo 2010; Luo 2011) reported the time for the resolution of wheezing, cough and pulmonary moist crackles. The pooled results of two trials show that infants treated with nebulised 3% saline had a shorter duration of respiratory symptoms and sign compared to those treated with nebulised 0.9% saline, with a pooled MD of -1.19 days (95% CI -1.54 to -0.84, P < 0.00001). There was significant heterogeneity in results between studies (P = 0.0005; I 2 statistic = 77.0%) (Analysis 1.7).
Duration of in-hospital oxygen supplementation
Not reported on.
Results of pulmonary function tests
Radiological findings
In two trials (Mandelberg 2003; Sarrell 2002) , the second chest radiograph was obtained on the third days after hospital admission.
The pooled results of two trials did not show significant difference in radiological score between the hypertonic saline group and the 0.9% saline group (pooled MD -0.08, 95% CI -0.90 to 0.75, P = 0.85) (Analysis 1.8). There was no significant heterogeneity between studies (P = 0.95; I 2 statistic = 0%).
10. Adverse events (tachycardia, hypertension, pallor, tremor, nausea, vomiting, diarrhea and acute urinary retention)
No significant adverse events related to hypertonic saline inhalation were observed in 11 trials. No patients were withdrawn from the trial by the medical staff because of adverse events or clinical deterioration. In the trial of Grewal 2009, three participants presented with vomiting and one presented with diarrhea during the study period. All four participants were enrolled in the 3% saline group, but these symptoms might not be directly related to nebulised hypertonic saline.
D I S C U S S I O N
Summary of main results
In this review, we defined the length of hospital stay as the primary outcome to measure the efficacy of nebulised hypertonic saline among inpatients with viral bronchiolitis. Despite differences in inhalation mixture and delivery intervals across the studies, the effect sizes of the treatment with 3% saline inhalation reported by six independent studies (Giudice 2012; Kuzik 2007; Luo 2010; Luo 2011; Mandelberg 2003; Tal 2006) were similar. That is, there was approximately a one-day reduction in the duration of hospitalisation. The pooled results from these five trials demonstrate that nebulised 3% saline could produce a reduction of 1.15 days in the mean length of hospital stay. This represents a 22.7% reduction from the mean length of hospitalisation in the normal saline group. Given the high prevalence of viral bronchiolitis in infants and the tremendous burden of this illness related to hospitalisation, this reduction may be considered clinically relevant and may potentially have a positive economic impact for both the health system and the individual families. The benefit of nebulised hypertonic saline in reducing the rate of hospitalisation was assessed by four trials, one in outpatients (Sarrell 2002) and three in emergency departments (Anil 2010; Grewal 2009; Ipek 2011) . The pooled results of these four trials showed a 37% reduction in the risk of hospitalisation among participants treated with 3% saline inhalation compared to those treated with 0.9% saline inhalation. However, this reduction was not statistically significant. Low statistical power due to small sample sizes may have contributed to this negative result. Further large RCTs are required to evaluate the efficacy of nebulised hypertonic saline in preventing hospitalisation among infants with acute viral bronchiolitis seen at outpatient setting or emergency department. The effects of hypertonic saline in reducing the rate of readmission were assessed by three emergency department trials (Al-Ansari 2010; Anil 2010; Grewal 2009). The pooled results of three trials did not demonstrate significant benefits of nebulised hypertonic saline in reducing the risk of readmission. Caution should be taken when interpreting the results of these three emergency department-based trials, given the small number of participants, the small number of inhalations (up to three doses) and short monitoring time (up to 120 minutes post-inhalation). Further large RCTs with multiple doses of hypertonic saline over a longer period of time are still needed. Clinical score is generally considered a relatively objective measure to assess the severity of illness. There are two clinical severity scoring systems more commonly used by randomised trials involving infants with viral bronchiolitis. One is a Respiratory Distress Assessment Instrument (RDAI) which assesses chest retractions and auscultatory findings, and provides a score ranging from 0 to 17, with a higher score indicating more severe respiratory distress (Lowell 1987) . The other scoring system, initially described by Wang, assesses respiratory rate, wheezing, retraction and general condition, providing a score ranging from 0 to 12, with increased severity receiving a higher score (Wang 1992) . In this review, seven trials utilised the clinical severity score system proposed by Wang 1992. The pooled results from these seven trials (one outpatient, one emergency department and five inpatient) demonstrate a statistically significant lower mean post-inhalation score among infants treated with 3% saline inhalation compared to those treated with 0.9% saline inhalation in the first three days of treatment.
The magnitude of reduction in the severity score produced by 3% saline inhalation may be considered clinically relevant because it represents a reduction of up to 29% from the mean clinical score in the 0.9% saline group. The benefits of nebulised hypertonic saline in improving clinical score are observed in both outpatients and inpatients, but not in emergency department patients over a short period of time (30 to 120 minutes). There is significant heterogeneity across studies regarding effect size of hypertonic saline on clinical score, especially between inpatient trials. We used post hoc meta-regression to explore the possible causes of heterogeneity, however, the small number of studies allowed us to include only the severity of bronchiolitis in the model and no significant association was found between the severity of disease and the effect size of hypertonic saline. Despite the substantial heterogeneity, the size of effect but not the direction of effect varies across studies, indicating that nebulised hypertonic saline is beneficial to different degrees in improving clinical score among infants with bronchiolitis. The potential effect modifiers have not been identified by this review, but they may include patient characteristics and treatment regimens. The potential side effects, principally acute bronchospasm, remain a concern with nebulised hypertonic saline. This review included 560 infants receiving hypertonic saline (3% saline: n = 503; 5% saline: n = 57) in repeated doses and no significant adverse events were reported. In nine trials ( , the study protocol defined the use of nebulised 3% saline alone, but bronchodilators were added into the study solution in 60% of the treatments by attending physicians. Only 57 patients in the trial of Luo 2011 and 30 patients in the trial of Ipek 2011 used 3% saline alone. Therefore, this review could not provide convincing evidence regarding the safety of nebulised hypertonic saline alone in infants with viral bronchiolitis. Given the possibility of acute bronchospasm induced by hypertonic saline in asthmatics and the difficulty in distinguishing between asthma and viral bronchiolitis in infants, it would seem reasonable to administer hypertonic saline in conjunction with bronchodilators to avoid any possible broncho-constrictive effect. The safety of nebulised hypertonic saline, even in higher concentration (5% to 7%), has recently been reported in patients with cystic fibrosis (Wark 2009) and the authors attributed the good safety profile of the therapy to the co-administration of hypertonic saline with bronchodilators.
In the trial of Al-Ansari 2010, no significant adverse events were observed among 57 patients receiving nebulised 5% saline mixed with 1.5 ml of epinephrine. The inhalation therapy was administrated via jet nebulisers in all but one trial (Tal 2006) , in which ultrasonic nebulisers were used. Theoretically, there are some differences in the physical properties of aerosols produced by jet nebulisers and ultrasonic nebulisers, which may affect their therapeutical efficacies. On the one hand, ultrasonic nebulisers induce sputum more efficiently than jet nebulisers. On the other hand, jet nebulisers generate aerosols with smaller aerodynamic mass median diameter which may more easily reach smaller bronchi and bronchioles. This review could not provide direct evidence regarding the impact of the physical properties of aerosols generated by different types of nebulisers, on the efficacy of inhaled hypertonic saline in infants with viral bronchiolitis. However, at least one trial ( and all trials failed to show significant effects of hypertonic saline in improving clinical score/oxygen saturation or in reducing the risk of hospitalisation/readmission. These results may suggest that nebulised hypertonic saline is effective for acute bronchiolitis only when the treatment is given at multiple daily doses during a reasonable period of time.
The concentration of nebulised hypertonic saline was 3% in all but one trial (Al-Ansari 2010). In this emergency department trial, two concentrations of hypertonic saline (3% and 5%) were used. No superiority of 5% saline over 3% saline was observed in improving clinical score at 24 hours and 48 hours after randomisation. However, further studies are still needed to establish the optimal concentration and treatment regime of nebulised hypertonic saline in infants with viral bronchiolitis.
Overall completeness and applicability of evidence
This review included trials conducted in both high-income and low-income countries and in different settings (inpatient, outpatient and emergency department). Thus evidence derived from this review may have a wide applicability. However, all 11 trials included in this review recruited only infants with mild to moderate bronchiolitis, so caution should be taken when extrapolating the findings of this review to patients with more severe bronchiolitis, such as those requiring mechanical ventilation, intensive care or having an oxygen saturation reading below 85% on room air. The underlying airway pathological changes may differ between severe and mild to moderate bronchiolitis, so different responses to treatments with hypertonic saline may be expected in more severe cases. Further trials are needed to assess the potential effects of nebulised hypertonic saline in infants hospitalised with severe acute bronchiolitis.
Quality of the evidence
All but one of the 11 included trials are of high methodological quality with low risk of bias. However, some methodological considerations should be mentioned. analysis. This analysis strategy aims to maintain the unbiased group comparison afforded by randomisation and to deal with the problem of non-compliance and protocol deviation. As the number of participants withdrawn after randomisation was small in all these trials, the lack of application of an intention-to-treat principle was unlikely to cause significant bias. Secondly, the sample size of this review was relatively small and the statistical power of the study might be not sufficient for some outcome measures, such as rate of hospitalisation and rate of readmission among outpatients or emergency department patients. The small number of studies included in the review also precludes an analytic approach to heterogeneity across studies, however, this is a substantial heterogeneity only for clinical score but not other outcomes.
Potential biases in the review process
The strength of this review is that all but one of the included trials have high quality and low risk of bias. The main concern regarding potential biases of this review is publication bias. We did not use funnel plots or other analytic approaches to deal with the potential publication bias, given the lack of reliable methods and relatively small number of included studies.
Agreements and disagreements with other studies or reviews
To the best of our knowledge, there is no other systematic review or traditional narrative review which assesses the efficacy and safety of nebulised hypertonic saline in infants with acute bronchiolitis. We also failed to find observational studies that address this question. This precludes a comparison of findings between this review and other studies.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Nebulised 3% saline produces a 1.2 day reduction in the mean length of hospital stay, compared to nebulised normal saline, among infants hospitalised with non-severe acute bronchiolitis. This therapy also significantly reduces clinical severity score among outpatients and inpatients with mild to moderate bronchiolitis. Given the clinically relevant benefit and good safety profile, nebulised 3% saline used in conjunction with bronchodilators should be considered an effective and safe treatment for infants with mild to moderate acute viral bronchiolitis.
Implications for research
Further large randomised controlled trials, preferably multi-centred, are still required to evaluate the effectiveness of nebulised hypertonic saline in infants with acute viral bronchiolitis, principally in infants who attend the emergency department and infants hospitalised with severe acute bronchiolitis. The optimal delivery intervals, duration of treatment and concentration of saline, and the most effective delivery devices remain to be determined. The mechanism of action of nebulised hypertonic saline in patients with viral bronchiolitis also needs to be addressed in future studies. Group 1: nebulised 5% hypertonic saline (5 ml) plus 1.5 ml of epinephrine Group 2: nebulised 3% hypertonic saline (5 ml) plus 1.5 ml of epinephrine Control groups: nebulised 0.9% normal saline (5 ml) plus 1.5 ml of epinephrine The treatment was given every 4 hours, until the patient was ready for discharge. Nebulised medications were delivered through a tight-fitting face mask by pressurised oxygen with the flow meter set at 10 L/min Age: mean age 9.5 months, range 1.5 to 24 months Inclusion criteria: infants with diagnosis of bronchiolitis, which required a history of upper respiratory infection and the presence of bilateral wheezing and/or crackles on chest auscultation, plus clinical severity score between 1 and 9 Exclusion criteria: prematurity, any underlying disease (e.g. cystic fibrosis, bronchopulmonary dysplasia and cardiac or renal disease), prior history of wheezing, atopic dermatitis, allergic rhinitis or asthma, oxygen saturation (SaO 2 ) < 85% on room air, CS score > 9, obtunded consciousness, progressive respiratory failure requiring mechanical ventilation, previous treatment with bronchodilators, and any steroid therapy within 2 weeks Interventions Test groups: Group 1: nebulised 3% hypertonic saline (4 ml) plus 1.5 mg of epinephrine Group 2: nebulised 3% hypertonic saline (4 ml) plus 2.5 mg of salbutamol Control groups: Group 3: nebulised 0.9% normal saline (4 ml) plus 1.5 mg of epinephrine Group 4: nebulised 0.9% normal saline (4 ml) plus 2.5 mg of salbutamol Group 5: nebulised 0.9% normal saline (4 ml Exclusion criteria: pre-existing cardiac or pulmonary disease, previous diagnosis of asthma by a physician, any previous use of bronchodilators (except for treatment of the current illness), severe disease requiring resuscitation room care, inability to take medication using a nebuliser, inability to obtain informed consent secondary to a language barrier, or no phone access for follow-up Interventions Test group: nebulised 3% hypertonic saline (2.5 ml) plus 0.5 ml of 2.25% racaemic epinephrine Control group: nebulised 0.9% normal saline (2.5 ml) plus 0.5 ml of 2.25% racaemic epinephrine Both groups received inhalation solutions at 0 minutes. Each treatment was given by
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Al-Ansari 2010
nebuliser with continuous flow of oxygen at 6 L/min. Two doses of the study drug were available for each patient such that, if the physician felt that a second dose of racaemic epinephrine was needed during the 120-minute study period, the patient received the same drug combination again Score (CBSS) of 4 to 8 on admission Exclusion criteria: infants with CBSS < 4 or > 8, oxygen saturation < 85% on room air, chronic cardiac illness, premature birth, birth weight < 2500 G, history of recurrent wheezing episodes, proven immune deficiency, severe neurological disease, age < 1 month or > 2 years, consolidation or atelectasis on a chest roentgenogram Interventions Test groups: Group 1: nebulised 3% hypertonic saline (4 ml) plus salbutamol 0.15 mg/kg Group 2: nebulised 3% hypertonic saline (4 ml) alone Control groups: Group 1: nebulised 0.9% hypertonic saline (4 ml) plus salbutamol 0.15 mg/kg Group 2: nebulised 0.9% hypertonic saline (4 ml) alone The treatment was given every 20 min until 3 doses had been administered (0, 20 and 40th min). All inhaled therapies were delivered via a compressor nebuliser through a facemask with continued flow of oxygen at 4e5 L/min (Minicompressor nebuliser, CN-02WD, Ace-Tec Co., Ltd., Guangdong, China) Age: mean age 4.7 months, range 10 days to 18 months Inclusion criteria: infants with diagnosis of moderately severe bronchiolitis, which required a history of a preceding viral upper respiratory infection, the presence of wheezing or crackles on chest auscultation, plus either an oxygen saturation of < 94% in room air or RDAI score of >= 4 Exclusion criteria: previous episode of wheezing, chronic cardiopulmonary disease or immunodeficiency, critical illness at presentation requiring admission to intensive care, the use of nebulised HS within the previous 12 hours, or premature birth (gestational age <= 34 weeks)
Interventions
Test group: nebulised 3% hypertonic saline (4 ml) Control group: nebulised 0.9% normal saline (4 ml) The treatment was given every 2 hours for 3 doses, followed by every 4 hours for 5 doses, followed by every 6 hours until discharge. All inhaled therapies were delivered to a settled infant from a standard oxygen-driven hospital nebuliser through a tight-fitting face-mask, or head box, whichever was better tolerated by the infant 
Test group: nebulised 3% hypertonic saline (4 ml) Control group: nebulised 0.9% normal saline (4 ml) The treatment was given every 2 hours for 3 doses, followed by every 4 hours for 5 doses, followed by every 6 hours until discharge. All inhaled treatments were delivered to infants from standard air-compressed nebulisers (PARI Corporation, Starnford, Germany) Test for overall effect: Z = 6.65 (P < 0.00001)
Test for subgroup differences: Chi 2 = 0.62, df = 2 (P = 0.73), I 2 =0.0% (1974 ( to November 2007 and LILACS (November 2007) .
A D D I T I O N A L T A B L E S
The following search terms were combined with the highly sensitive search strategy as recommended by The Cochrane Collaboration (Dickersin 1994) to search MEDLINE. These terms were adapted to search CENTRAL, EMBASE and LILACS as required.
MEDLINE (OVID)
1 exp Bronchiolitis/ 2 bronchiolit$.mp. 
Date Event Description
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Given the very limited number of studies that were identified initially, we added the comparison of nebulised hypertonic saline alone versus nebulised 0.9% saline. We also clarified the population according to the age and changed the title to specify infants.
